Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


A single centre, double blind, randomised, parallel group, single dose signal study of R-107 in participants with DSM-5 specific phobia


To see complete record on anzctr.org.au, please visit this link

Id: ACTRN12618001381279p

Organisation Name: Douglas Pharmaceuticals Ltd

Overal Status: Withdrawn

Start Date: 10/09/2018

Brief Summary: This is a single centre, double blind, randomised, parallel group, single-dose signal study of R-107 in participants with DSM-5 specific phobia to spiders. 12 participants will be randomised to receive a single dose of either R-107 or placebo. The hypothesis is that compared with placebo, R-107 will reduce anxiety self-ratings and avoidance behaviour associated with exposure to a phobic object (spider) in participants known to have a specific phobia according to DSM-5 criteria. Participants will complete several assesments prior to receiveing the dose, and then again 3 hours and 72 hours later.

Countries:
  • New Zealand
  • Dunedin


Total execution time in seconds: 0.11983704566956